Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Medtronic
Boehringer Ingelheim
Express Scripts
Johnson and Johnson
Moodys

Last Updated: November 26, 2022

CLINICAL TRIALS PROFILE FOR PEMETREXED DISODIUM


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Pemetrexed Disodium

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00003706 ↗ LY231514 in Treating Patients With Locally Advanced or Metastatic Solid Tumors and Varying Degrees of Kidney Function Completed Lily Research Laboratories Phase 1 1998-04-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemotherapy drugs may have different effects in patients with different degrees of kidney function. PURPOSE: Phase I trial to study the effectiveness of LY231514 in treating patients who have locally advanced or metastatic solid tumors and varying degrees of kidney function.
NCT00003706 ↗ LY231514 in Treating Patients With Locally Advanced or Metastatic Solid Tumors and Varying Degrees of Kidney Function Completed National Cancer Institute (NCI) Phase 1 1998-04-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemotherapy drugs may have different effects in patients with different degrees of kidney function. PURPOSE: Phase I trial to study the effectiveness of LY231514 in treating patients who have locally advanced or metastatic solid tumors and varying degrees of kidney function.
NCT00003706 ↗ LY231514 in Treating Patients With Locally Advanced or Metastatic Solid Tumors and Varying Degrees of Kidney Function Completed The University of Texas Health Science Center at San Antonio Phase 1 1998-04-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemotherapy drugs may have different effects in patients with different degrees of kidney function. PURPOSE: Phase I trial to study the effectiveness of LY231514 in treating patients who have locally advanced or metastatic solid tumors and varying degrees of kidney function.
NCT00003711 ↗ Combination Chemotherapy in Treating Patients With Metastatic Solid Tumors Completed San Antonio Cancer Institute Phase 1 1997-09-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy with pemetrexed disodium and irinotecan in treating patients who have metastatic solid tumors.
NCT00005636 ↗ Cisplatin With or Without Pemetrexed Disodium in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot be Removed by Surgery Completed National Cancer Institute (NCI) Phase 3 1999-11-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if cisplatin is more effective with or without pemetrexed disodium for malignant mesothelioma of the pleura. PURPOSE: Randomized phase III trial to compare the effectiveness of cisplatin with or without pemetrexed disodium in treating patients who have malignant mesothelioma of the pleura that cannot be removed by surgery.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Pemetrexed Disodium

Condition Name

Condition Name for Pemetrexed Disodium
Intervention Trials
Lung Cancer 29
Stage IV Non-Small Cell Lung Cancer 14
Unspecified Adult Solid Tumor, Protocol Specific 9
Stage IIIA Non-Small Cell Lung Cancer 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Pemetrexed Disodium
Intervention Trials
Lung Neoplasms 69
Carcinoma, Non-Small-Cell Lung 57
Mesothelioma 12
Carcinoma 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Pemetrexed Disodium

Trials by Country

Trials by Country for Pemetrexed Disodium
Location Trials
United States 975
China 32
Canada 15
United Kingdom 9
Spain 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Pemetrexed Disodium
Location Trials
Ohio 40
Illinois 37
California 35
Michigan 35
North Carolina 34
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Pemetrexed Disodium

Clinical Trial Phase

Clinical Trial Phase for Pemetrexed Disodium
Clinical Trial Phase Trials
Phase 4 1
Phase 3 16
Phase 2 62
[disabled in preview] 27
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Pemetrexed Disodium
Clinical Trial Phase Trials
Completed 57
Terminated 19
Recruiting 12
[disabled in preview] 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Pemetrexed Disodium

Sponsor Name

Sponsor Name for Pemetrexed Disodium
Sponsor Trials
National Cancer Institute (NCI) 80
Alliance for Clinical Trials in Oncology 12
Eli Lilly and Company 10
[disabled in preview] 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Pemetrexed Disodium
Sponsor Trials
Other 110
NIH 80
Industry 20
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
AstraZeneca
Mallinckrodt
Medtronic
Express Scripts
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.